Diagnosing ASD in Adults Without ID: Accuracy of the ADOS-2 and the ADI-R / L. FUSAR-POLI in Journal of Autism and Developmental Disorders, 47-11 (November 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3370-3379 Titre : Diagnosing ASD in Adults Without ID: Accuracy of the ADOS-2 and the ADI-R Type de document : Texte imprimé et/ou numérique Auteurs : L. FUSAR-POLI, Auteur ; Natascia BRONDINO, Auteur ; M. ROCCHETTI, Auteur ; Cristina PANISI, Auteur ; U. PROVENZANI, Auteur ; S. DAMIANI, Auteur ; Pierluigi POLITI, Auteur Article en page(s) : p.3370-3379 Langues : Anglais (eng) Mots-clés : Adi-r  Ados  Adult  Autism  Dsm-5  Diagnosis Index. décimale : PER Périodiques Résumé : Diagnosing autism spectrum disorder (ASD) in adulthood often represents a challenge in clinical practice. The aim of the present study was to evaluate the sensitivity and specificity of the ADOS and ADI-R in diagnosing ASD in adults. 113 subjects with an IQ of 70 or above were assessed through an extensive clinical evaluation. The ADOS-2 Module 4 and the ADI-R were separately administered by staff members blind to clinical judgment. Our results cautiously confirm the accuracy of ADOS-2 Module 4, while suggest that ADI-R might not be reliable in adults without intellectual disability. Clinicians' training and experience remains of primary importance while assessing adults who could potentially belong to the autism spectrum. En ligne : http://dx.doi.org/10.1007/s10803-017-3258-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324 [article] Diagnosing ASD in Adults Without ID: Accuracy of the ADOS-2 and the ADI-R [Texte imprimé et/ou numérique] / L. FUSAR-POLI, Auteur ; Natascia BRONDINO, Auteur ; M. ROCCHETTI, Auteur ; Cristina PANISI, Auteur ; U. PROVENZANI, Auteur ; S. DAMIANI, Auteur ; Pierluigi POLITI, Auteur . - p.3370-3379. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3370-3379 Mots-clés : Adi-r  Ados  Adult  Autism  Dsm-5  Diagnosis Index. décimale : PER Périodiques Résumé : Diagnosing autism spectrum disorder (ASD) in adulthood often represents a challenge in clinical practice. The aim of the present study was to evaluate the sensitivity and specificity of the ADOS and ADI-R in diagnosing ASD in adults. 113 subjects with an IQ of 70 or above were assessed through an extensive clinical evaluation. The ADOS-2 Module 4 and the ADI-R were separately administered by staff members blind to clinical judgment. Our results cautiously confirm the accuracy of ADOS-2 Module 4, while suggest that ADI-R might not be reliable in adults without intellectual disability. Clinicians' training and experience remains of primary importance while assessing adults who could potentially belong to the autism spectrum. En ligne : http://dx.doi.org/10.1007/s10803-017-3258-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324

Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies / Natascia BRONDINO in Journal of Autism and Developmental Disorders, 46-3 (March 2016)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 46-3 (March 2016) . - p.825-839 Titre : Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies Type de document : Texte imprimé et/ou numérique Auteurs : Natascia BRONDINO, Auteur ; Laura FUSAR-POLI, Auteur ; Cristina PANISI, Auteur ; Stefano DAMIANI, Auteur ; Francesco BARALE, Auteur ; Pierluigi POLITI, Auteur Article en page(s) : p.825-839 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  GABA  Clinical trials  Systematic review Index. décimale : PER Périodiques Résumé : Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings. En ligne : http://dx.doi.org/10.1007/s10803-015-2619-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=281 [article] Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies [Texte imprimé et/ou numérique] / Natascia BRONDINO, Auteur ; Laura FUSAR-POLI, Auteur ; Cristina PANISI, Auteur ; Stefano DAMIANI, Auteur ; Francesco BARALE, Auteur ; Pierluigi POLITI, Auteur . - p.825-839. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 46-3 (March 2016) . - p.825-839 Mots-clés : Autism spectrum disorder  GABA  Clinical trials  Systematic review Index. décimale : PER Périodiques Résumé : Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings. En ligne : http://dx.doi.org/10.1007/s10803-015-2619-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=281

What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials / Umberto PROVENZANI in Autism, 24-2 (February 2020)  

Public ISBD [article]  inAutism > 24-2 (February 2020) . - p.274-284 Titre : What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials Type de document : Texte imprimé et/ou numérique Auteurs : Umberto PROVENZANI, Auteur ; Laura FUSAR-POLI, Auteur ; Natascia BRONDINO, Auteur ; Stefano DAMIANI, Auteur ; Marco VERCESI, Auteur ; Nicholas MEYER, Auteur ; Matteo ROCCHETTI, Auteur ; Pierluigi POLITI, Auteur Article en page(s) : p.274-284 Langues : Anglais (eng) Mots-clés : autism spectrum disorder  core symptoms  outcome measures  systematic review  trials Index. décimale : PER Périodiques Résumé : The number of trials aimed at evaluating treatments for autism spectrum disorder has been increasing progressively. However, it is not clear which outcome measures should be used to assess their efficacy, especially for treatments which target core symptoms. The present review aimed to provide a comprehensive overview regarding the outcome measures used in clinical trials for people with autism spectrum disorder. We systematically searched the Web of Knowledge(SM) database between 1980 and 2016 to identify published controlled trials investigating the efficacy of interventions in autism spectrum disorder. We included 406 trials in the final database, from which a total of 327 outcome measures were identified. Only seven scales were used in more than 5% of the studies, among which only three measured core symptoms (Autism Diagnostic Observation Schedule, Childhood Autism Rating Scale, and Social Responsiveness Scale). Of note, 69% of the tools were used in the literature only once. Our systematic review has shown that the evaluation of efficacy in intervention trials for autism spectrum disorder relies on heterogeneous and often non-specific tools for this condition. The fragmentation of tools may significantly hamper the comparisons between studies and thus the discovery of effective treatments for autism spectrum disorder. Greater consensus regarding the choice of these measures should be reached. En ligne : http://dx.doi.org/10.1177/1362361319854641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415 [article] What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials [Texte imprimé et/ou numérique] / Umberto PROVENZANI, Auteur ; Laura FUSAR-POLI, Auteur ; Natascia BRONDINO, Auteur ; Stefano DAMIANI, Auteur ; Marco VERCESI, Auteur ; Nicholas MEYER, Auteur ; Matteo ROCCHETTI, Auteur ; Pierluigi POLITI, Auteur . - p.274-284. Langues : Anglais (eng) in Autism > 24-2 (February 2020) . - p.274-284 Mots-clés : autism spectrum disorder  core symptoms  outcome measures  systematic review  trials Index. décimale : PER Périodiques Résumé : The number of trials aimed at evaluating treatments for autism spectrum disorder has been increasing progressively. However, it is not clear which outcome measures should be used to assess their efficacy, especially for treatments which target core symptoms. The present review aimed to provide a comprehensive overview regarding the outcome measures used in clinical trials for people with autism spectrum disorder. We systematically searched the Web of Knowledge(SM) database between 1980 and 2016 to identify published controlled trials investigating the efficacy of interventions in autism spectrum disorder. We included 406 trials in the final database, from which a total of 327 outcome measures were identified. Only seven scales were used in more than 5% of the studies, among which only three measured core symptoms (Autism Diagnostic Observation Schedule, Childhood Autism Rating Scale, and Social Responsiveness Scale). Of note, 69% of the tools were used in the literature only once. Our systematic review has shown that the evaluation of efficacy in intervention trials for autism spectrum disorder relies on heterogeneous and often non-specific tools for this condition. The fragmentation of tools may significantly hamper the comparisons between studies and thus the discovery of effective treatments for autism spectrum disorder. Greater consensus regarding the choice of these measures should be reached. En ligne : http://dx.doi.org/10.1177/1362361319854641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415

---

1 (1 - 3 / 3)